Tengion IPO brings in $30M

Tengion has raised $30 million in an IPO, falling short of the $40 million the company had hoped to raise. Shares priced at $5; the company was hoping to hit the $8 to $10 range. Tengion is the fourth biotech to go public this year, according to Renaissance Capital. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.